



ENDO2022

NOW AVAILABLE: ENDO 2022 SESSION RECORDINGS

Accreditation

Internet Activity Accreditation

- **Title of the activity:** ENDO 2022 Session Recordings Bundle
- Release date: 02/06/2023
- Expiration date: 12/31/24

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.



AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 74 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.



For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

CREDIT CLAIM DEADLINES

- December 31, 2024

CREDIT CLAIM INSTRUCTIONS

1. Visit education.endocrine.org
 2. Select "My Courses" or the Home icon on the left-hand side
 3. Search for and click on ENDO 2022 Session Recordings
 4. View all sessions of interest
2. Upon completion of each session, complete brief evaluation and claim credit.
 3. Once you have viewed all sessions for which you wish to receive credit, complete the overall course evaluation to obtain your certificate

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The following AMSC members reported relevant financial relationships:

- **Andrew Bauer**, MD, Speaker: Hexal, AG
- **Antonio Bianco**, MD, PhD, Consulting Fee: Allergan, BLA Technology, IBSA Foudnation, Synthonics

- **Kristien Boelaert**, MD, PhD, Advisory Board: Pfizer, Eisai
- **Massimiliano Caprio**, MD, PhD, Grant Recipient: Bayer AG
- **Bart Clarke**, MD, Advisory Board: Bristol-Myers Squibb; Consulting Fee: Shire/Takeda, Inc., Calcilytix, Inc., Amolyt, Inc.
- **Carolyn L. Cummins**, PhD, Member, American Association of Pharmaceutical Scientists, Canadian Society of Pharmaceutical Sciences; Reviewer and Grantee: Canadian Institutes of Health Research
- **Dawn Davis**, MD, PhD, Employee: Department of Veterans Affairs; Grant Recipient: Department of Veterans Affairs, NIH
- **Scott M. Dehm**, PhD, Executive Committee: Society for Basic Urologic Research; Grantee and Reviewer: NIH; Consultant: Janssen Research and Development LLC, Celgene
- **Marie B. Demay**, MD, Reviewer and Grantee, NIH
- **Daniel Dumesic**, MD, Advisory Board: Spruce BioSciences Inc.; Grant Recipient: NIH
- **Lauren Fishbein**, MD, PhD, Advisory Board: PheoPara Alliance; Consulting Fee: Lantheus/Azedra; Member: American Association of Clinical Endocrinologists, North American Neuroendocrine Tumor Society, Women in Endocrinology; Co-Lead PheoPara Working Group: A5
- **Aime T. Franco**, PhD, Board of Directors, Co-Chair Trainees and Education Committee, Co-Chair of ATA Grant Program Review Task Force: American Thyroid Association
- **Matthew Freeby**, MD, Grant Recipient: Novo Nordisk, Abbott Diabetes
- **Daniel E. Frigo**, PhD, Consultant and Grant Recipient: GTx, Inc.
- **Adda Grimberg**, MD, Advisory Board: Pfizer; Consulting Fee: Sandoz; Grant Recipient: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- **Aylin C. Hanyaloglu**, PhD, Grant Panel Member: Studium Institute for Advanced Studies; Associate Editor: Frontiers for Endocrinology; Consultant: Merck
- **Niki Karavitaki**, FRCP, PhD, Advisory Board: Recordati Rare Diseases, Pfizer, Ipsen; Speaker: HRA Pharma, Pfizer, Ipsen
- **Marta Korbonits**, MD, PhD, Speaker: Pfizer, Ipsen; Associate Editor: JES, Endocrine Society; Scientific Advisor: ONO, NovoNordisk, Corcept; Investigator: Crinetics
- **Stephane A. Laporte**, PhD, Editorial Board Member: Journal of Biological Chemistry; Collaborator: Domain Therapeutics NA Inc.
- **Monica M. Laronda**, PhD, Advisory Board Member: Dimension Inx; Section Editor: Reproductive Biomedicine Online (RBMO)
- **Maria Veronica Mericq**, MD, Advisory Board: Pfizer, Sandoz, Merck, Novo Nordisk; Consultant Fee: Novartis/Sandoz; Grant Recipient: Merck

- **Nicola Napoli**, MD, PhD, Advisory Board: UCB; Consultant: Abiogen, UCB
- **Gabrielle Page-Wilson**, MD, Advisory Board: Strongbridge Biopharma, Recordati Rare Diseases, Inc., Xeris BioPharma; Consultant: Xeris BioPharma
- **Robin Peeters**, MD, PhD, Advisory Board: Sanofi Genzyme, Bayer; Speaker: Berlin-Chemie, Goodlife Fertility BV, Institut Biochimique SA (IBSA), Sanofi Genzyme, Bayer, EISAI, Program Organizing Committee Annual Meeting: American Thyroid Association; Focus Area Lead: Program Organizing Committee, European Society for Endocrinology; Member: European Thyroid Association
- **Jennifer Sherr**, MD, PhD, Advisory Board: Bigfoot Biomedical, Lilly, Insulet, Cecelia Health; Consultant Fee: Medtronic Diabetes, Sanofi; Grant Recipient: JDRF, Reviewer: JDRF
- **Robert Wermers**, MD, Meeting Program Committee: American Association of Clinical Endocrinology Bone and Calcium Disease State Network; Editor: Bone and Calcium ASAP Section
- **Selma F. Witchel**, MD, Annual Meeting Program Committee: Pediatric Endocrine Society; Member: Androgen Excess-PCOS Society; Editorial Board Member, Journal of Clinical Endocrinology & Metabolism, Journal of the Endocrine Society, Sex Development; Associate Editor: Steroids
- **Maria-Christina Zennaro**, MD, PhD, Member: Société Française d'Endocrinology, Société Française de Caridologie, European Network for the Study of Adrenal Tumors; Executive Committee: International Aldosterone Conference; President: European Section of Aldosterone Council (ESAC)-France; French network on adrenal tumors COMETE
- **Bulent Okan Yildiz**, MD, Reproductive and Developmental Endocrinology Clinical Lead: European Society of Endocrinology

The following AMSC members reported no relevant financial relationships:

Ernesto Bernal-Mizrachi, MD; **Stephanie Fish**, MD; **Stephen R. Hammes**, PhD, MD; **Kendall W. Nettles**, PhD; **Margareta Pisarska**, MD; **Inez Rogatsky**, PhD; **Philipp Scherer**, PhD; **Marc J. Tetel**, PhD

Disclosure information for presenters is included in their individual recorded presentations.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.